CSI Market
Sign In | Register

Acurx Pharmaceuticals inc (ACXP) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACXP Annual Cash Flow →
The data below summarizes Acurx Pharmaceuticals inc's cash flow activity from Jun 30 2025 to Jun 30 2026, enabling a period-by-period view of cash movement.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-3.94
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.46
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Share Based Payment To Vendors0.06
Gain On Forgiveness Of Paycheck Protection Program Loan-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts and Other Receivables0.05
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.41
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.15
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.25
Discontinued operations0.00
Net Cash flow from Operating Activities-3.12
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Registered Direct Offering Costs January-
Registered Direct Offering Costs March-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net6.22
Proceeds From Paycheck Protection Program Loan Cares Act-
Proceeds From Issuance Of Private Placement Net Of Issuance Costs-
Sale Of Stock Consideration Received On Transaction-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents7.56
Share Offering Costs Incurred But Not Yet Paid-
Proceeds From Issuance Of Common Stock In Connection With Equity Line Of Credit Net3.11
Proceeds From March2025 Registered Direct Offering Net Of Issuance Costs-
Proceeds From January2025 Registered Direct Offering Net Of Issuance Costs-
Proceeds From At Market Offering Net Of Issuance Costs-
Proceeds Warrant Exercises Net-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities6.22
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-3.12
Total Cash Flow3.10
4 historic quarters locked

Sign in to unlock the full Acurx Pharmaceuticals inc cash flow history.

Sign In Create Free Account

About Acurx Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001104659-26-095904

Figures are derived from filed reports and may be restated. Historical data is subject to revision.